Bio-Rad Laboratories stocks experienced a tumultuous streak as highlighted by multiple events.
Van ECK Associates Corp cut their holdings while
RBC Capital reduced Bio-Rad's price target. The company's Q4 earnings and revenues missed estimates leading to a 4% stock drop. A notable increase in trading volume followed an earnings beat.
Strategic Financial Concepts LLC made a significant $3.56 million investment and despite oversold conditions, Bio-Rad shares continued to slump. Stake reductions from
Entropy Technologies LP and
Allspring Global Investments Holdings LLC further applied pressure. Meanwhile, major acquisition plans were set with Bio-Rad’s eyes on
Stilla's Next-Gen Digital Platform. Increased short interest raised concerns while quarterly earnings beat expectations. Despite a lower price target set by
Wells Fargo & Company, other firms like
Lecap Asset Management Ltd. and
Sumitomo Mitsui Trust Group Inc. maintained significant positions.
Oncocyte secured substantial funding from Bio-Rad to advance transplant diagnostics. Bio-Rad’s stock future remains uncertain as conservatism continues to hold back full potential despite positive financial performance. Finally, the announcement of a stock repurchase program offers a ray of optimism in this bleak environment.
Bio-Rad Laboratories Stocks News Analytics from Thu, 21 Jun 2018 02:34:36 GMT to Sat, 15 Feb 2025 23:10:08 GMT -
Rating -3
- Innovation -7
- Information 3
- Rumor -5
